X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/04/15/2863093/0/en/New-Novartis-Fabhalta-iptacopan-data-show-clinically-meaningful-and-statistically-significant-proteinuria-reduction-of-38-3-versus-placebo-for-patients-with-IgA-nephropathy-IgAN.html
https://www.fiercepharma.com/pharma/novartis-touts-surrogate-endpoint-win-nabs-priority-review-fabhalta-igan
https://www.novartis.com/news/media-releases/novartis-fabhalta-iptacopan-receives-positive-chmp-opinion-first-oral-monotherapy-adult-patients-paroxysmal-nocturnal-hemoglobinuria-pnh
https://www.fiercepharma.com/pharma/novartis-roll-newly-approved-fabhalta-touts-its-promise-another-rare-blood-disease
https://www.prnewswire.com/news-releases/novartis-receives-fda-approval-for-fabhalta-iptacopan-offering-superior-hemoglobin-improvement-in-the-absence-of-transfusions-as-the-first-oral-monotherapy-for-adults-with-pnh-302007024.html
https://www.globenewswire.com/news-release/2023/11/20/2782908/0/en/Novartis-showcases-significant-data-updates-from-Kisqali-iptacopan-and-Scemblix-at-SABCS-and-ASH.html
https://www.fiercebiotech.com/biotech/analyst-applauds-novartis-iptacopan-faultless-performance-phase-3-kidney-trial-pharma-tees#:~:text=Analyst%20applauds%20Novartis'%20'faultless',in%20phase%203%20kidney%20trial&text=Novartis'%20investigational%20oral%20factor%20B,track%20FDA%20approval%20next%20year.
https://www.globenewswire.com/news-release/2023/04/26/2654733/0/en/Novartis-Phase-III-APPOINT-PNH-trial-shows-investigational-oral-monotherapy-iptacopan-improves-hemoglobin-to-near-normal-levels-leading-to-transfusion-independence-in-all-treatment.html
https://www.fiercebiotech.com/biotech/ash-novartis-says-rare-disease-med-stands-its-own-diving-deeper-head-head-win-against
https://www.fiercebiotech.com/biotech/novartis-takes-another-swipe-astrazenecas-rare-disease-gems-soliris-and-ultomiris
https://www.prnewswire.com/news-releases/novartis-highlights-scientific-advances-with-kisqali-iptacopan-scemblix-and-ytb323-data-at-sabcs-and-ash-301685230.html
https://www.novartis.com/news/media-releases/novartis-investigational-oral-monotherapy-iptacopan-demonstrates-clinically-meaningful-superiority-over-anti-c5-treatment-phase-iii-apply-pnh-study
https://www.fiercebiotech.com/biotech/novartis-eyeing-3b-market-beats-astrazeneca-blockbuster-phase-3-trigger-race-regulators
https://www.pharmatimes.com/news/novartis_iptacopan_hits_endpoints_in_mid-stage_study_1383048
https://www.prnewswire.com/news-releases/novartis-iptacopan-meets-primary-endpoints-in-phase-ii-study-in-rare-kidney-disease-c3-glomerulopathy-c3g-301416937.html
http://www.pmlive.com/pharma_news/novartis_iptacopan_scores_positive_results_in_rare_blood_disorder_pnh_1371614
https://www.reuters.com/article/us-novartis-fda/novartis-gets-fda-breakthrough-therapy-tag-for-experimental-iptacopan-idUSKBN28Q0NN
https://www.clinicaltrialsarena.com/news/novartis-iptacopan-reduces-proteinuria/
Market Place
Share 
